Clinical trial Recruiting at 1 site Observational Ages 18 to 50 Women only

Non-invasive embryo genetic screening in egg donation cycles

Official title: Non-invasive Preimplantation Genetic Screening (niPGTA) in Oocyte Donation Patients.

Run by Instituto Bernabeu · NCT07364526 · Data updated 2026-11-12

This will test whether a non-invasive genetic test of the embryo culture fluid can predict implantation and pregnancy outcomes for people receiving donated eggs.

Quick facts

Study typeObservational
Ages18 Years to 50 Years
SexWomen only
Enrollment164 (estimated)
SponsorInstituto Bernabeu
Academic / other
Locations1 site (Alicante)
StatusRecruiting
StartedFebruary 26, 2026
Main results expectedMarch 1, 2027
Study endsDecember 1, 2027
Registry record updatedJanuary 23, 2026
Trial IDNCT07364526 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are oocyte recipients aged 18–50 planning a single blastocyst transfer with a partner who has normal sperm FISH and who can give informed consent.

Probably not a fit

Patients with uterine malformations, abnormal parental karyotypes, or those not undergoing single blastocyst donor transfers (or who cannot consent) are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, blinded, non-selection study in women receiving donor oocytes who undergo single blastocyst transfer. Embryos will be chosen for transfer using standard morphological criteria only, and the spent culture medium will be collected without influencing clinical decisions. Cell-free embryonic DNA in the spent medium will be analyzed by next-generation sequencing to detect chromosomal aneuploidies (niPGTA). The study will compare niPGTA results from transferred embryos that implant or lead to ongoing pregnancy versus those that fail to implant or result in pregnancy loss.

Why it matters

Potential benefit: If successful, this could allow clinicians to identify embryos at higher risk of implantation failure or miscarriage without performing an invasive embryo biopsy.

How similar studies have gone: Other studies of non-invasive PGT‑A have shown mixed results, with some promising concordance but variable reliability, so its clinical value in egg donation cycles remains unproven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women between 18 and 50 years old who are oocyte recipients.
* Signed consent form
* Transfer of a single blastocyst-stage embryo
* Male with normal sperm FISH

Exclusion Criteria:

* Uterine malformations
* Abnormal karyotypes in either partner
* Failure to sign informed consent

Where it's running

  • Instituto Bernabeu
    Alicante, Spain
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.